PriceTargets.com logo

Achilles Therapeutics - ACHL Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $4.00
  • Forecasted Upside: 280.95%
  • Number of Analysts: 3
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.05 As of 11/21/2024 11:17 AM ET
▼ -0.02 (-1.87%)

This chart shows the closing price for ACHL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Achilles Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACHL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACHL

Analyst Price Target is $4.00
▲ +280.95% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Achilles Therapeutics in the last 3 months. The average price target is $4.00, with a high forecast of $6.00 and a low forecast of $2.00. The average price target represents a 280.95% upside from the last price of $1.05.

This chart shows the closing price for ACHL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 3 investment analysts is to hold stock in Achilles Therapeutics. This rating has held steady since November 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/5/2024Chardan CapitalLower TargetBuy ➝ Buy$11.00 ➝ $6.00
4/5/2024Piper SandlerReiterated RatingOverweight ➝ Neutral$8.00 ➝ $2.00
12/14/2023Bank of AmericaReiterated RatingBuy ➝ Underperform
8/7/2023Chardan CapitalReiterated RatingBuy ➝ Buy$11.00
3/8/2023Chardan CapitalLower Target$17.00 ➝ $12.00
12/6/2022OppenheimerDowngradeOutperform ➝ Market Perform
12/6/2022Piper SandlerLower TargetOverweight$10.00 ➝ $8.00
12/6/2022Chardan CapitalLower TargetBuy$20.00 ➝ $17.00
5/27/2022Piper SandlerLower Target$17.00 ➝ $10.00
5/10/2022Piper SandlerLower Target$20.00 ➝ $17.00
3/1/2022Piper SandlerLower Target$23.00 ➝ $20.00
8/10/2021Piper SandlerLower TargetOverweight$25.00 ➝ $23.00
7/7/2021Chardan CapitalReiterated RatingBuy
5/3/2021JPMorgan Chase & Co.Initiated CoverageUnderweight$11.00
4/26/2021JPMorgan Chase & Co.Initiated CoverageUnderweight
4/26/2021Chardan CapitalInitiated CoverageBuy$27.00
4/26/2021Piper SandlerInitiated CoverageOverweight$25.00
4/26/2021OppenheimerInitiated CoverageOutperform$23.00
4/26/2021Bank of AmericaInitiated CoverageBuy$20.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.16 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024

Current Sentiment

  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Achilles Therapeutics logo
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $1.05
Low: $1.05
High: $1.06

50 Day Range

MA: $0.98
Low: $0.71
High: $1.07

52 Week Range

Now: $1.05
Low: $0.63
High: $1.76

Volume

7,563 shs

Average Volume

453,288 shs

Market Capitalization

$43.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.35

Frequently Asked Questions

What sell-side analysts currently cover shares of Achilles Therapeutics?

The following Wall Street analysts have issued reports on Achilles Therapeutics in the last year: Bank of America Co., Chardan Capital, and Piper Sandler.
View the latest analyst ratings for ACHL.

What is the current price target for Achilles Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Achilles Therapeutics in the last year. Their average twelve-month price target is $4.00, suggesting a possible upside of 273.8%. Chardan Capital has the highest price target set, predicting ACHL will reach $6.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $2.00 for Achilles Therapeutics in the next year.
View the latest price targets for ACHL.

What is the current consensus analyst rating for Achilles Therapeutics?

Achilles Therapeutics currently has 1 sell rating, 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ACHL, but not buy more shares or sell existing shares.
View the latest ratings for ACHL.

What other companies compete with Achilles Therapeutics?

Other companies that are similar to Achilles Therapeutics include Nkarta, Galectin Therapeutics, DiaMedica Therapeutics, Instil Bio and MediWound. Learn More about companies similar to Achilles Therapeutics.

How do I contact Achilles Therapeutics' investor relations team?

Achilles Therapeutics' physical mailing address is 245 HAMMERSMITH ROAD, LONDON X0, W6 8PW. The company's listed phone number is 44-0-20-8154-4600 and its investor relations email address is [email protected]. The official website for Achilles Therapeutics is www.achillestx.com. Learn More about contacing Achilles Therapeutics investor relations.